Related Experiment Videos
Myeloid leukemia 239Pu-treated mice
Abstract:
Incidence of myeloid leukemia was studied in 79 mice injected i.v. with 180 kBq 239Pu/kg. Plutonium-treated mice were compared with 70 controls of the same origin and sex (random-bred ICR-SPF female mice). The animals were killed moribund and the disease was diagnosed on the basis of histological and cytologic examination of bone marrow, spleen, liver, peripheral blood, and other tissues. It has been found that 22 plutonium-treated mice (27.8%) and 17 controls (24.3%) were leukemic. The mean survival of diseased animals was 459 +/- 19 days in the tested group and 559 +/- 24 days in controls. It means that the occurrence of myeloid leukemia was not very different in irradiated and control mice, but under plutonium contamination the disease appeared significantly earlier and its incidence was shifted to the younger age.
Insights
Plutonium-239 exposure did not significantly alter myeloid leukemia incidence in mice. However, plutonium contamination caused the disease to appear earlier and at a younger age in affected animals.
Area of Science:
- Toxicology
- Radiobiology
- Oncology
Background:
- Investigating the long-term health effects of internal radionuclide exposure is crucial for understanding radiation-induced diseases.
- Plutonium-239 (Pu) is a significant internal emitter with known carcinogenic potential.
- Myeloid leukemia is a serious hematological malignancy that can be influenced by environmental factors.
Purpose of the Study:
- To determine the incidence of myeloid leukemia in mice following intravenous administration of Plutonium-239 (Pu).
- To compare the occurrence and onset of myeloid leukemia in Pu-treated mice versus control groups.
- To analyze the impact of Pu contamination on the age of disease onset and survival rates.
Main Methods:
- Intravenous injection of 180 kBq 239Pu/kg into 79 female ICR-SPF mice.
- Comparison with a control group of 70 female ICR-SPF mice.
- Histological and cytologic examination of bone marrow, spleen, liver, peripheral blood, and other tissues in moribund animals for disease diagnosis.
Main Results:
- Myeloid leukemia incidence was 27.8% in plutonium-treated mice (22/79) and 24.3% in controls (17/70).
- Mean survival for diseased animals was significantly shorter in the plutonium group (459 ± 19 days) compared to controls (559 ± 24 days).
- Plutonium contamination led to an earlier onset of myeloid leukemia, shifting incidence towards younger ages.
Conclusions:
- While Plutonium-239 (Pu) did not drastically increase overall myeloid leukemia incidence in this mouse model, it significantly accelerated disease onset.
- The findings highlight the importance of internal alpha-emitter exposure in accelerating the development of radiation-related cancers.
- Further research into the mechanisms of accelerated carcinogenesis by internal emitters is warranted.